Cargando…
502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
BACKGROUND: COVID-19 disproportionately results in hospitalization and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody that binds a highly conserved epitope of the SARS-CoV-2 receptor binding domain and has an Fc modification that...
Autores principales: | Gupta, Anil K, Rojas, Yaneicy Gonzalez, Juarez, Erick, Casal, Manuel Crespo, Moya, Jaynier, Falci, Diego Rodrigues, Sarkis, Elias H, Solis, Joel, Zheng, Hanzhe, Scott, Nicola, Cathcart, Andrea L, Hebner, Christy, Sager, Jennifer, Mogalian, Erik, Austin, Daren, Peppercorn, Amanda, Alexander, Elizabeth L, Yeh, Wendy W, Free, Almena, Brinson, Cynthia, Aldinger, Melissa, Shapiro, Adrienne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644137/ http://dx.doi.org/10.1093/ofid/ofab466.701 |
Ejemplares similares
-
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial
por: Shapiro, Adrienne E, et al.
Publicado: (2023) -
1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19
por: Gupta, Anil K, et al.
Publicado: (2022) -
1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab
por: Agostini, Maria L, et al.
Publicado: (2022) -
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19
por: Sager, Jennifer E., et al.
Publicado: (2023) -
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023)